Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...
Comprehensive study exposes critical health risks of obesity, including diabetes, heart disease, and cancer, while offering ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...
Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, ...
The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback